000			02054cam a2200277 4500500
005			20250121154737.0
041			_afre
042			_adc
100	1	0	_aFrechet, Laure _eauthor
700	1	0	_a Puzenat, Eve _eauthor
700	1	0	_a Charollais, Romain _eauthor
700	1	0	_a Dresco, Flora _eauthor
700	1	0	_a Carlet, Clémentine _eauthor
700	1	0	_a Gallais-Serezal, Irène _eauthor
700	1	0	_a Nardin, Charlée _eauthor
700	1	0	_a Aubin, François _eauthor
245	0	0	_aDissecting cellulitis of the scalp treated by tumour necrosis factor inhibitors: a case series
260			_c2021.
500			_a50
520			_aBackground: Dissecting cellulitis of the scalp (DCS), also known as Hoffmann disease or perifolliculitis capitis abscedens et suffodiens, is a rare disease characterized by chronic inflammation of the scalp. Treatment is difficult and often disappointing. Objectives: To report our experience of TNF inhibitors in a series of patients with DCS. Materials & Methods: We conducted a monocentric retrospective study of nine patients with DCS treated with TNF blocker after failure of other conventional treatments. Results: After a mean duration of treatment by TNF inhibitors of 17 ± 16 months, four patients (44% versus 0%) had a Physician's Global Assessment score of 0 or 1. We observed a 67% reduction in the number of inflammatory nodules, an 88% reduction in purulent drainage and a 45% improvement in Dermatology Life Quality Index. The mean treatment satisfaction index was 6.6 ± 1.6 out of 10. Conclusion: Our study suggests that TNF inhibitors are effective against disease activity and may improve quality of life in the management of DCS refractory to conventional treatments.
690			_ainfliximab
690			_aadalimumab
690			_aissecting cellulitis of the scalp
786	0		_nEuropean Journal of Dermatology | 31 | 1 | 2021-01-01 | p. 81-85 | 1167-1122
856	4	1	_uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2021-1-page-81?lang=en&redirect-ssocas=7080
999			_c603198 _d603198